Natalizumab and Chronic Inflammation
NCT05177718
·
clinicaltrials.gov ↗
PHASE4
Phase
TERMINATED
Status
1
Enrollment
OTHER
Sponsor class
Stopped
Sponsor declined further support
Conditions
Multiple Sclerosis
Interventions
DRUG:
Natalizumab 300 MG in 15 ML Injection
Sponsor
Vanderbilt University Medical Center
Collaborators
[object Object]